3176 results for «372»
3176 results
What is new in atrioventricular valves?
19 May 2025 – From EuroPCR 2025
Discover the latest advancements in atrioventricular valve interventions, including innovative transcatheter repair technologies and first-in-human experiences with novel devices.
Nurses and allied professionals abstracts session
20 May 2025 – From EuroPCR 2025
Highlight the pivotal role of nurses and allied health professionals in interventional cardiology through a series of abstracts addressing radial haemostasis, TAVI nursing programs, early mobilization, radiation protection, and physiologist-led intracoronary thermodilution assessments.
New solutions for old problems
19 May 2025 – From EuroPCR 2025
Discover new solutions addressing persistent cardiovascular challenges, including novel diagnostic systems, vascular closure devices, specialized transcatheter closure technologies, and innovative stent-graft systems.
Complex PCI in calcific coronary artery disease - LIVE Case
20 May 2025 – From EuroPCR 2025
A 76-year-old male patient presented with a significant history of coronary artery disease: CABG with LIMA/LAD and RIMA/OM (1996), RCA PCI with BVS (2016), OM PCI (2017), RIMA occlusion and OM retenosis treated with DCB (2022) with preserved LV. He was admitted for pre-operative evaluation prior...
Mitral hotline: new devices
20 May 2025 – From EuroPCR 2025
Stay updated on emerging devices in mitral valve repair and replacement with this session covering novel technologies including transcatheter edge-to-edge repair (TEER), posterior leaflet restoration, transfemoral mitral annuloplasty, and a first-in-human transseptal TMVR system. Clinical trial data and early feasibility experiences provide valuable insights into advancing...
Stable CAD and multivessel disease
20 May 2025 – From EuroPCR 2025
This session delves into the management of stable coronary artery disease (CAD) with multivessel involvement. Learn how clinical and procedural factors influence revascularisation strategies, debate the merits of complete revascularisation, and explore decision-making processes between anatomical and functional approaches through illustrative cases and expert analysis.
Managing TAVI complications
20 May 2025 – From EuroPCR 2025
Gain expertise in managing TAVI complications including strategic retrieval of embolized valves, handling unexpected additional valve usage, managing left ventricle suicide phenomenon, and integrating coronary intervention tools during structural heart procedures, supported by instructive case series.
From crossroads to crossovers: cracking the left main code
20 May 2025 – From EuroPCR 2025
Navigate complex scenarios in left main coronary artery interventions with this session focusing on protected left main and multivessel disease, IVUS-guided PCI, stent optimization, and in-stent restenosis management. Real-world cases from Azerbaijan, Moldova, and Iraq provide collaborative insights and innovative strategies for challenging coronary anatomy.
LAA closure and anthrombotic therapies
21 May 2025 – From EuroPCR 2025
Explore contemporary evidence on left atrial appendage (LAA) closure and associated antithrombotic therapies. This session covers strategies for antithrombotic de-escalation, efficacy and safety in patients with anticoagulation contraindications, breakthrough stroke etiology, and anatomical considerations in high-risk atrial fibrillation patients undergoing ablation.
Updates in transcatheter MVR
21 May 2025 – From EuroPCR 2025
This session provides a detailed overview of recent advances in transcatheter mitral valve replacement (TMVR). Examine outcomes from next-generation transcatheter heart valves, long-term clinical data from mitral valve-in-valve and valve-in-ring procedures, and explore innovative approaches including transseptal MVR with insights from global studies.
Coronary scaffolds: new developments and applications
21 May 2025 – From EuroPCR 2025
Stay informed on advancements in coronary scaffolds with this session reviewing new developments and applications. Topics include comparative performance of magnesium-based bioresorbable stents, long-term clinical outcomes from the BIOMAG-I and FANTOM BRS studies, and real-world experiences with next-generation thin-strut scaffolds.
Coronary sinus reducer for microvascular angina
28 Feb 2020
A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...
Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation – The WATCH-TAVR Trial
26 Oct 2023
Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.
Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis
22 Mar 2022
Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022.
Author
Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3
02 Apr 2025
Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.
Author
